RestructuringJun 22, 2026, 09:22 AM
Jaguar Health Explores Strategic Alternatives to Maximize Value
AI Summary
Jaguar Health, Inc. announced that its Board of Directors has initiated a process to explore a range of strategic alternatives aimed at maximizing shareholder value. This exploration aligns with the anticipated completion of clinical work supporting a New Drug Application (NDA) for its crofelemer prescription drug candidate for rare intestinal failure diseases. Potential alternatives include mergers, acquisitions, partnerships, joint ventures, and licensing arrangements. The company highlighted the significant market opportunity for crofelemer, with the microvillus inclusion disease market estimated at $1.1 billion in 2026, projected to reach $1.5 billion by 2033.
Key Highlights
- Jaguar Health's Board initiated a process to explore strategic alternatives.
- The process aims to maximize shareholder value, aligning with crofelemer NDA filing.
- Potential alternatives include mergers, acquisitions, partnerships, and licensing arrangements.
- Crofelemer is being developed for rare intestinal failure diseases.
- The market for microvillus inclusion disease is estimated at $1.1 billion in 2026.
- This market is projected to rise to $1.5 billion by 2033.
- Crofelemer reduced parenteral support by up to 37% in a proof-of-concept trial.
- CEO Lisa Conte will present company updates on June 24, 2026.
Price Impact
More from JAGX